Table 1. Characteristics of studies included in the analysis: Ovarian Cancer Association Consortiuma.
| Study acronym | Study name | Study location, time of enrolment | Data collection method | Median time of follow-up, days (range of follow-up) | Determination of history of hyper/hypothyroidism | Patients with hyperthyroid disease, N (%) | Patients with hypothyroid disease, N (%) |
|---|---|---|---|---|---|---|---|
| AUS (Merritt et al, 2008) | Australian Ovarian Cancer Study | Australia, Jan 2002 to Jun 2006 | Self-completed questionnaire | 1705 (19-3672) | Q: Ever having disease requiring regular medical care | 10 (0.9) | 27 (2.3) |
| DOV (Rossing et al, 2007; Bodelon et al, 2012) | Disease of the Ovary and their Evaluation Study | USA: Washington, 2002–2005 (DOV) 2006–2009 (DVE) | In-person interview | 1398 (243–3192) | Q: Disease diagnosed by physician or health care professional before being diagnosed with ovarian cancer | 13 (2.6) | 100 (16.7) |
| GER (Royar et al, 2001) | German Ovarian Cancer Study | Germany, 1993–1996 | Self-administered questionnaire | 1464 (18–6060) | Q: Ever having disease diagnosed by physician | 10 (4.4) | 7 (3.1) |
| HAW (Goodman et al, 2008; Lurie et al, 2008) | Hawaii Ovarian Cancer Study | USA: Hawaii, 1993–2008 | In-person interview | 2750 (143–7662) | Q: Disease diagnosed by physician before being diagnosed with ovarian cancer | 22 (4.6) | 25 (5.2) |
| HJO (Song et al, 2009) | Hannover-Jena Ovarian Cancer Study | Germany 2007–2011 | MRR | 707 (9–8722) | MRR: reporting of disease | 7 (5.4) | 29 (19.1) |
| HOP (Lo-Ciganic et al, 2012) | Hormones and Ovarian Cancer Prediction Study | USA: Pennsylvania, Ohio, and New York, 2003–2009 | In-person interview and MRR | 1821 (40–3982) | Q: Disease diagnosed by physician or health care professional before being diagnosed with ovarian cancer; MRR: reporting of disease | 25 (4.2) | 109 (16.1) |
| JPN (Hamajima et al, 2001) | Hospital-based Research Program at Aichi Cancer Center | Japan, 2001–2005 | In-person interview | 1069 (43–3396) | Q: Ever having disease | 2 (3.1) | 0 |
| LAX | Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute | USA: California, 1989 to present | MRR | 1498 (13–8239) | MRR: reporting of disease | 3 (1.1) | 56 (17.3) |
| NCO (Schildkraut et al, 2008, 2010) | North Carolina Ovarian Cancer Study | USA: North Carolina, 1999–2008 | Self-completed questionnaire | 1836 (93–5730) | Q: Disease diagnosed by physician before being diagnosed with ovarian cancer | 32 (3.9) | 133 (14.3) |
| NEC (Terry et al, 2005; Merritt et al, 2013) | New England Case-Control Study of Ovarian Cancer | USA: New Hampshire and Massachusetts, 1992–2003 | In-person interview | 2904 (70–7709) | Q: Ever having disease before being diagnosed with ovarian cancer | 25 (3.3) | 97 (11.6) |
| NJO (Bandera et al, 2011; Chandran et al, 2011; Gifkins et al, 2012) | New Jersey Ovarian Cancer Study | USA: New Jersey, 2002–2008 | Phone interview | 2375 (165–4085) | Q: Disease diagnosed by health care professional before being diagnosed with ovarian cancer | 11 (5.4) | 41 (17.7) |
Abbreviations: MRR=medical record review; Q=question.
a
JPN did not provide information on the age at being diagnosed with hyper- or hypothyroid disease; LAX did not provide information on the age at being diagnosed with hyperthyroidism; AUS patients were not specifically asked about thyroid disease, and thyroid disease history was determined from the answers to the open-ended question on having other diseases; HJO, LAX, NEC and NJO collected information on anti-hyper- and anti-hypothyroid medication intake.